Verfügbarkeit: Pharmaceutical and medical device safety

Pharmaceutical and medical device safety: a study in public and private regulation

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Macleod, Sonia (VerfasserIn), Chakraborty, Sweta (VerfasserIn)
Format:	Buch
Sprache:	English
Veröffentlicht:	Oxford Hart Publishing 2019 Baden-Baden Nomos 2019 München C.H.Beck 2019
Ausgabe:	First published
Schriftenreihe:	Civil justice systems
Schlagworte:	Produzentenhaftung Arzneimittelüberwachung Internationales Wirtschaftsrecht Medizinprodukt USA Großbritannien Medizinprodukterecht Haftung Litigation Pharmaprodukte Produkthaftung medical device sector
Online-Zugang:	Inhaltstext Inhaltsverzeichnis
Beschreibung:	xxi, 298 Seiten Diagramme
ISBN:	9781509916696 9783848754632 9783406737145

Internformat

MARC


LEADER	00000nam a22000008c 4500
001	BV045278756
003	DE-604
005	20191113
007	t
008	181108s2019 gw \|\|\|\| \|\|\|\| 00\|\|\| eng d
015			\|a 18,N41 \|2 dnb
016	7		\|a 1168341817 \|2 DE-101
020			\|a 9781509916696 \|c (Hart Publishing) \|9 978-1-50991-669-6
020			\|a 9783848754632 \|c Festeinband : circa EUR 80.00 (DE) : (Nomos) \|9 978-3-8487-5463-2
020			\|a 9783406737145 \|c (CH Beck) \|9 978-3-406-73714-5
024	3		\|a 9783848754632
035			\|a (DE-599)DNB1168341817
040			\|a DE-604 \|b ger \|e rda
041	0		\|a eng
044			\|a gw \|c XA-DE-BY
049			\|a DE-M382
084			\|a PT 319 \|0 (DE-625)139857: \|2 rvk
100	1		\|a Macleod, Sonia \|e Verfasser \|0 (DE-588)1178737772 \|4 aut
245	1	0	\|a Pharmaceutical and medical device safety \|b a study in public and private regulation \|c Sonia Macleod and Sweta Chakraborty
250			\|a First published
263			\|a 201903
264		1	\|a Oxford \|b Hart Publishing \|c 2019
264		1	\|a Baden-Baden \|b Nomos \|c 2019
264		1	\|a München \|b C.H.Beck \|c 2019
300			\|a xxi, 298 Seiten \|b Diagramme
336			\|b txt \|2 rdacontent
337			\|b n \|2 rdamedia
338			\|b nc \|2 rdacarrier
490	0		\|a Civil justice systems
650	0	7	\|a Produzentenhaftung \|0 (DE-588)4047375-2 \|2 gnd \|9 rswk-swf
650	0	7	\|a Arzneimittelüberwachung \|0 (DE-588)4437717-4 \|2 gnd \|9 rswk-swf
650	0	7	\|a Internationales Wirtschaftsrecht \|0 (DE-588)4027461-5 \|2 gnd \|9 rswk-swf
650	0	7	\|a Medizinprodukt \|0 (DE-588)4024018-6 \|2 gnd \|9 rswk-swf
651		7	\|a USA \|0 (DE-588)4078704-7 \|2 gnd \|9 rswk-swf
651		7	\|a Großbritannien \|0 (DE-588)4022153-2 \|2 gnd \|9 rswk-swf
653			\|a Medizinprodukterecht
653			\|a Haftung
653			\|a Litigation
653			\|a Pharmaprodukte
653			\|a Produkthaftung
653			\|a medical device sector
689	0	0	\|a Internationales Wirtschaftsrecht \|0 (DE-588)4027461-5 \|D s
689	0	1	\|a Medizinprodukt \|0 (DE-588)4024018-6 \|D s
689	0	2	\|a Produzentenhaftung \|0 (DE-588)4047375-2 \|D s
689	0		\|5 DE-604
689	1	0	\|a USA \|0 (DE-588)4078704-7 \|D g
689	1	1	\|a Großbritannien \|0 (DE-588)4022153-2 \|D g
689	1	2	\|a Arzneimittelüberwachung \|0 (DE-588)4437717-4 \|D s
689	1	3	\|a Produzentenhaftung \|0 (DE-588)4047375-2 \|D s
689	1		\|5 DE-604
700	1		\|a Chakraborty, Sweta \|e Verfasser \|0 (DE-588)1189153246 \|4 aut
710	2		\|a Nomos Verlagsgesellschaft \|0 (DE-588)117513-0 \|4 pbl
710	2		\|a Verlag C.H. Beck \|0 (DE-588)1023902869 \|4 pbl
776	0	8	\|i Erscheint auch als \|n Online-Ausgabe, PDF \|z 978-1-50991-672-6
776	0	8	\|i Erscheint auch als \|n Online-Ausgabe, PDF \|z 978-1-50991-673-3
856	4	2	\|m X:MVB \|q text/html \|u http://deposit.dnb.de/cgi-bin/dokserv?id=9d728e4b6ae64a19a144864a7e29a9f8&prov=M&dok_var=1&dok_ext=htm \|3 Inhaltstext
856	4	2	\|m DNB Datenaustausch \|q application/pdf \|u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030666384&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA \|3 Inhaltsverzeichnis
999			\|a oai:aleph.bib-bvb.de:BVB01-030666384

Datensatz im Suchindex

_version_	1804179050858545152
adam_text	CONTENTS FOREWORD BY CHRISTOPHER HODGES ................................................................................................ V ACKNOWLEDGEMENTS ...................................................................................................................... IX ABBREVIATIONS ............................................................................................................................ XIX 1. INTRODUCTION .......................................................................................................................... 1 I. THE LEGAL CONTEXT ...................................................................................................... 1 A. BASIS OF LIABILITY ................................................................................................ 10 B. LITIGATION SYSTEMS ............................................................................................ 11 C. FUNDING AND COSTS ........................................................................................... 11 D. US: THE CLASS ACTION AND MDL ...................................................................... 12 E. EUROPE ............................................................................................................... 14 F. SETTLEMENT SCHEMES .......................................................................................... 16 2. THE REGULATION OF MEDICINES AND MEDICAL DEVICES ......................................................... 17 I. MEDICINAL PRODUCTS .................................................................................................. 18 A. HISTORICAL DRUG/PHARMACEUTICAL REGULATION IN THE UK ................................ 18 I. 1948-59: THE BIRTH OF THE NATIONAL HEALTH SERVICE .............................. 21 II. 1959-62: THALIDOMIDE ............................................................................ 22 III. 1963-71: VOLUNTARY SELF-REGULATION ....................................................... 23 IV. 1971 ONWARDS: STATUTORY REGULATION ..................................................... 24 B. EUROPEAN REGULATION OF MEDICINAL PRODUCTS ................................................. 25 I. A BRIEF HISTORY OF EUROPEAN MEDICINAL PRODUCTS REGULATION ............ 26 II. CURRENT EU STRUCTURES AND PROCEDURES FOR REGULATING MEDICINAL PRODUCTS ................................................................................. 30 C. EUROPEAN REGULATION OF MEDICAL DEVICES ...................................................... 42 I. CLASSIFICATION AND STANDARDS .................................................................. 46 D. GENERAL PRODUCT SAFETY REGULATION IN EUROPE ............................................... 50 E. MEDICINAL PRODUCT REGULATION IN THE US ....................................................... 50 I. HISTORIC REGULATION OF MEDICINAL PRODUCTS IN THE US ......................... 51 II. CURRENT REGULATION OF MEDICINAL PRODUCTS IN THE US .......................... 56 III. MARKETING AUTHORISATIONS WITHIN THE US ............................................. 58 IV. REQUIREMENTS FOR DEVELOPING AND MARKETING MEDICINAL PRODUCTS IN THE US .................................................................................. 60 F. US REGULATION OF MEDICAL DEVICES ................................................................. 73 I. US CLASSIFICATION AND STANDARDS ............................................................ 73 3. DETAILED CASE DESCRIPTIONS AND REGULATORY HISTORIES .................................................... 82 I. TERATOGENS AND FOETAL DAMAGE ............................................................................... 82 A. THALIDOMIDE (ALPHA-PHTHALIMIDO-GLUTARIMIDE) ............................................. 82 I. DESCRIPTION ............................................................................................. 82 XII CONTENTS II. SAFETY ISSUE .............................................................................................. 82 III. MARKETING AND REGULATORY HISTORY ........................................................ 83 IV. LITIGATION ................................................................................................. 85 V. CONCLUSION .............................................................................................. 87 B. HORMONAL PREGNANCY TESTS - INCLUDING PRIMODOS ...................................... 88 I. DESCRIPTION ............................................................................................. 88 II. SAFETY ISSUE .............................................................................................. 88 III. MARKETING AND REGULATORY HISTORY ........................................................ 89 IV. LITIGATION ................................................................................................. 91 V. CONCLUSION .............................................................................................. 91 C. DIETHYLSTILBOESTROL (DES) ................................................................................ 92 I. DESCRIPTION ............................................................................................. 92 II. SAFETY ISSUE .............................................................................................. 92 III. MARKETING AND REGULATORY HISTORY ........................................................ 92 IV. LITIGATION ................................................................................................. 97 V. CONCLUSION .............................................................................................. 99 D. EPILIM/DEPAKOTE/DEPAKENE (SODIUM VALPROATE, VALPROIC ACID, MAGNESIUM VALPROATE, VALPROATE SEMISODIUM OR VALPROMIDE) .................. 100 I. DESCRIPTION ........................................................................................... 100 II. SAFETY ISSUE ............................................................................................ 100 III. MARKETING AND REGULATORY HISTORY ...................................................... 101 IV. LITIGATION ............................................................................................... 105 V. CONCLUSION ............................................................................................ 107 E. ACCUTANE/ROACCUTANE (ISOTRETINOIN) ........................................................... 108 I. DESCRIPTION ........................................................................................... 108 II. SAFETY ISSUE ............................................................................................ 108 III. MARKETING AND REGULATORY HISTORY ...................................................... 108 IV. LITIGATION ............................................................................................... 116 V. CONCLUSION ................................... 118 II. CONTRACEPTIVES AND HORMONE REPLACEMENT THERAPY .......................................... 119 A. GRAVIGARD OR COPPER 7 INTRAUTERINE DEVICE ................................................. 119 I. DESCRIPTION .............................................................................. 119 II. SAFETY ISSUE ............................................................................................ 119 III. MARKETING AND REGULATORY HISTORY ...................................................... 120 IV. LITIGATION ......................................... 121 V. CONCLUSION ............................................................................................ 124 B. THIRD-GENERATION ORAL CONTRACEPTIVES ........................................................ 125 I. DESCRIPTION ........................................................................................... 125 II. SAFETY ISSUE ............................................................................................ 125 III. MARKETING AND REGULATORY HISTORY ...................................................... 125 IV. LITIGATION ............................................................................................... 128 V. CONCLUSION ............................................................................................ 128 C. NORPLANT (LEVONORGESTREL) .............................................................................. 129 I. DESCRIPTION ........................................................................................... 129 II. SAFETY ISSUE ............................................................................................ 129 III. MARKETING AND REGULATORY HISTORY ...................................................... 129 CONTENTS XIII IV. LITIGATION ................................................................................................ 130 V. CONCLUSION ............................................................................................. 131 D. HORMONE REPLACEMENT THERAPY ................................................................... 132 I. DESCRIPTION ............................................................................................ 132 II. SAFETY ISSUE ............................................................................................. 132 III. MARKETING AND REGULATORY HISTORY ...................................................... 132 IV. LITIGATION ................................................................................................ 136 V. CONCLUSION ............................................................................................. 137 III. VACCINES ................................................................................................................... 138 A. DTP VACCINE ................................................................................................... 138 I. DESCRIPTION ............................................................................................ 138 II. SAFETY ISSUE ............................................................................................. 138 III. MARKETING AND REGULATORY HISTORY ...................................................... 139 IV. LITIGATION ................................................................................................ 142 V. CONCLUSION ............................................................................................. 144 B. MMR VACCINE ................................................................................................ 145 I. DESCRIPTION ............................................................................................ 145 II. SAFETY ISSUE ............................................................................................. 147 III. MARKETING AND REGULATORY HISTORY ...................................................... 147 IV. LITIGATION ............................................................................................... 148 V. CONCLUSION ............................................................................................ 149 IV. NEUROMODULATORS ................................................................................................... 150 A. BENZODIAZEPINES ............................................................................................ 150 I. DESCRIPTION ........................................................................................... 150 II. SAFETY ISSUE ............................................................................................ 150 III. MARKETING AND REGULATORY HISTORY ...................................................... 150 IV. LITIGATION ............................................................................................... 151 V. CONCLUSION ............................................................................................ 153 B. MERITAL (NOMIFENSINE) .................................................................................... 154 I. DESCRIPTION ........................................................................................... 154 II. SAFETY ISSUE ............................................................................................ 154 III. MARKETING AND REGULATORY HISTORY ...................................................... 154 IV. LITIGATION ............................................................................................... 156 V. CONCLUSION ............................................................................................ 156 C. SELECTIVE SEROTONIN REUPTAKE INHIBITORS ...................................................... 157 I. DESCRIPTION ........................................................................................... 157 II. SAFETY ISSUES .......................................................................................... 157 III. MARKETING AND REGULATORY HISTORY ...................................................... 159 IV. LITIGATION ............................................................................................... 161 V. CONCLUSION ............................................................................................ 163 D. SABRIL (VIGABATRIN) .......................................................................................... 164 I. DESCRIPTION ........................................................................................... 164 II. SAFETY ISSUE ............................................................................................ 164 III. MARKETING AND REGULATORY HISTORY ...................................................... 164 IV. LITIGATION ............................................................................................... 165 V. CONCLUSION .................................................... 165 XIV CONTENTS E. MIRAPEXIN/SIFROL/DAQUIRAN (PRAMIPEXOLE) .................................................. 166 I. DESCRIPTION ............................................................................................ 166 II. SAFETY ISSUE ............................................................................................. 166 III. MARKETING AND REGULATORY HISTORY ...................................................... 167 IV. LITIGATION ............................................................................................... 168 V. CONCLUSION ............................................................................................ 169 V. NON-STEROIDAL ANTI-INFLAMMATORIES ...................................................................... 170 A. OPREN (BENOXAPROFEN) ................................................................................... 170 I. DESCRIPTION ............................................................................................ 170 II. SAFETY ISSUE ............................................................................................. 170 III. MARKETING AND REGULATORY HISTORY ...................................................... 170 IV. LITIGATION ............................................................................................... 171 V. CONCLUSION ............................................................................................ 172 B. VIOXX (ROFECOXIB) ............................................................................................ 173 I. DESCRIPTION ........................................................................................... 173 II. SAFETY ISSUE ............................................................................................ 173 III. MARKETING AND REGULATORY HISTORY ...................................................... 174 IV. LITIGATION ............................................................................................... 175 V. CONCLUSION ............................................................................................ 176 VI. PANCREATIC FUNCTION (ENDOCRINE AND EXOCRINE) AND OBESITY TREATMENTS ......................................................................................... 177 A. ADIFAX/ISOMERIDE/REDUX (DEXFENFLURAMINE) AND PONDERAX (FENFLURAMINE) ................................................................................................ 177 I. DESCRIPTION ........................................................................................... 177 II. SAFETY ISSUE ............................................................................................ 177 III. MARKETING AND REGULATORY HISTORY ...................................................... 178 IV. LITIGATION ............................................................................................... 179 V. CONCLUSION ............................................................................................ 180 B. MEDIATOR (BENFLUOREX) ................................................................................... 181 I. DESCRIPTION ........................................................................................... 181 II. SAFETY ISSUE ............................................................................................ 181 III. MARKETING AND REGULATORY HISTORY ...................................................... 181 IV. LITIGATION ............................................................................................... 184 V. CONCLUSION ............................................................................................ 184 C. HUMAN INSULIN ............................................................................................... 185 I. DESCRIPTION ........................................................................................... 185 II. ALLEGED SAFETY ISSUE .............................................................................. 185 III. MARKETING AND REGULATORY HISTORY ...................................................... 187 IV. LITIGATION ............................................................................................... 188 V. CONCLUSION ............................................................................................ 189 D. PANCREATIC ENZYMES ....................................................................................... 190 I. DESCRIPTION ........................................................................................... 190 II. SAFETY ISSUE ............................................................................................ 190 III. MARKETING AND REGULATORY HISTORY ...................................................... 190 IV. LITIGATION ............................................................................................... 192 V. CONCLUSION ............................................................................................ 192 CONTENTS XV VII. CONTAMINATED HUMAN-TISSUE-DERIVED PRODUCTS .............................................. 193 A. BLOOD PRODUCTS ............................................................................................. 193 I. DESCRIPTION ........................................................................................... 193 II. SAFETY ISSUE ........................................................................................... 193 III. MARKETING AND REGULATORY HISTORY .................................................... 194 IV. LITIGATION .............................................................................................. 194 V. CONCLUSION ........................................................................................... 196 B. HUMAN GROWTH HORMONE ........................................................................... 197 I. DESCRIPTION ........................................................................................... 197 II. SAFETY ISSUE ........................................................................................... 197 III. MARKETING AND REGULATORY HISTORY .................................................... 197 IV. LITIGATION .............................................................................................. 197 V. CONCLUSION ........................................................................................... 197 VIII. CARDIOVASCULAR PHARMACEUTICALS ......................................................................... 198 A. ERALDIN (PRACTOLOL) ........................................................................................ 198 I. DESCRIPTION ........................................................................................... 198 II. SAFETY ISSUE ........................................................................................... 198 III. MARKETING AND REGULATORY HISTORY .................................................... 198 IV. LITIGATION ............................................................................................. 199 V. CONCLUSION .......................................................................................... 200 B. MANOPLAX (FLOSEQUINAN) ............................................................................... 201 I. DESCRIPTION .......................................................................................... 201 II. SAFETY ISSUE .......................................................................................... 201 III. MARKETING AND REGULATORY HISTORY .................................................... 201 IV. LITIGATION ............................................................................................. 203 V. CONCLUSION .......................................................................................... 203 C. LIPOBAY (CERIVASTATIN) .................................................................................. 204 I. DESCRIPTION .......................................................................................... 204 II. SAFETY ISSUE .......................................................................................... 204 III. MARKETING AND REGULATORY HISTORY .................................................... 205 IV. LITIGATION ............................................................................................. 207 V. CONCLUSION .......................................................................................... 207 IX. ANTI-PROTOZOAN MEDICATIONS .............................................................................. 208 A. EMAFORM, ENTERO-FORM OR CHINOFORM (CLIOQUINOL) ................................. 208 I. DESCRIPTION .......................................................................................... 208 II. SAFETY ISSUE .......................................................................................... 208 III. MARKETING AND REGULATORY HISTORY .................................................... 209 IV. LITIGATION ............................................................................................. 210 V. CONCLUSION .......................................................................................... 211 B. LARIAM (MEFLOQUINE) ................................................................................... 212 I. DESCRIPTION .......................................................................................... 212 II. SAFETY ISSUE .......................................................................................... 212 III. MARKETING AND REGULATORY HISTORY .................................................... 212 IV. LITIGATION ............................................................................................. 215 V. CONCLUSION .......................................................................................... 216 XVI CONTENTS X. BREAST AND OTHER COSMETIC IMPLANTS ................................................................... 217 A. DOW-CORNING SILICONE IMPLANTS ................................................................. 217 I. DESCRIPTION ........................................................................................... 217 II. SAFETY ISSUE ............................................................................................ 217 III. MARKETING AND REGULATORY HISTORY ...................................................... 218 IV. LITIGATION ............................................................................................... 219 V. CONCLUSION ............................................................................................ 220 B. TRILUCENT BREAST IMPLANTS ............................................................................. 221 I. DESCRIPTION ........................................................................................... 221 II. SAFETY ISSUE ............................................................................................ 221 III. MARKETING AND REGULATORY HISTORY ...................................................... 221 IV. LITIGATION ............................................................................................... 222 V. CONCLUSION ............................................................................................ 223 C. POLY IMPLANT PROTHESE (PIP) HYDROGEL BREAST IMPLANTS ............................. 224 I. DESCRIPTION ........................................................................................... 224 II. SAFETY ISSUE ............................................................................................ 224 III. MARKETING AND REGULATORY HISTORY ...................................................... 225 IV. LITIGATION ............................................................................................... 225 V. CONCLUSION ............................................................................................ 227 D. POLY IMPLANT PROTHESE (PIP) IMGHC SILICONE BREAST IMPLANTS ................ 228 I. DESCRIPTION ........................................................................................... 228 II. SAFETY ISSUE ............................................................................................ 228 III. MARKETING AND REGULATORY HISTORY ..................................................... 230 IV. LITIGATION..... .......................................................................................... 232 V. CONCLUSION ............................................................................................ 234 XI. URINARY INCONTINENCE AND PELVIC PROLAPSE TREATMENTS ...................................... 235 A. MICTURIN (TERODILINE) ..................................................................................... 235 I. DESCRIPTION ........................................................................................... 235 II. SAFETY ISSUE ............................................................................................ 235 III. MARKETING AND REGULATORY HISTORY ..................................................... 235 IV. LITIGATION ............................................................................................... 236 V. CONCLUSION ............................................................................................ 236 B. UROGYNAECOLOGICAL MESH ............................................................................... 237 I. DESCRIPTION ............................................................................................ 237 II. SAFETY ISSUE ............................................................................................ 238 III. MARKETING AND REGULATORY HISTORY ..................................................... 239 IV. LITIGATION ............................................................................................... 259 V. CONCLUSION ............................................................................................ 264 4. CONCLUSIONS ...................................................................................................................... 265 I. PREVENTION IS BETTER THAN A CURE ............................................................................ 266 II. ADVERSE EVENT REPORTING ....................................................................................... 266 III. CORRELATION OR CAUSATION? ..................................................................................... 269 IV. THRESHOLDS .............................................................................................................. 269 V. PRODUCT WITHDRAWALS .......................................... 272 CONTENTS XVII VI. COMPENSATION OR REDRESS? ................................................................................. 274 VII. PUBLIC REGULATION V PRIVATE REGULATION .............................................................. 278 A. COMPENSATION - REDRESS ............................................................................. 278 B. DETERRENCE .................................................................................................... 280 VIII. CONCLUSIONS .......................................................................................................... 280 INDEX ......................................................................................................................................... 283
any_adam_object	1
author	Macleod, Sonia Chakraborty, Sweta
author_GND	(DE-588)1178737772 (DE-588)1189153246
author_facet	Macleod, Sonia Chakraborty, Sweta
author_role	aut aut
author_sort	Macleod, Sonia
author_variant	s m sm s c sc
building	Verbundindex
bvnumber	BV045278756
classification_rvk	PT 319
ctrlnum	(DE-599)DNB1168341817
discipline	Rechtswissenschaft
edition	First published
format	Book
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03063nam a22007218c 4500</leader><controlfield tag="001">BV045278756</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20191113 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">181108s2019 gw \|\|\|\| \|\|\|\| 00\|\|\| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">18,N41</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1168341817</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781509916696</subfield><subfield code="c">(Hart Publishing)</subfield><subfield code="9">978-1-50991-669-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783848754632</subfield><subfield code="c">Festeinband : circa EUR 80.00 (DE) : (Nomos)</subfield><subfield code="9">978-3-8487-5463-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783406737145</subfield><subfield code="c">(CH Beck)</subfield><subfield code="9">978-3-406-73714-5</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783848754632</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1168341817</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BY</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-M382</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PT 319</subfield><subfield code="0">(DE-625)139857:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Macleod, Sonia</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1178737772</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical and medical device safety</subfield><subfield code="b">a study in public and private regulation</subfield><subfield code="c">Sonia Macleod and Sweta Chakraborty</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">First published</subfield></datafield><datafield tag="263" ind1=" " ind2=" "><subfield code="a">201903</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford</subfield><subfield code="b">Hart Publishing</subfield><subfield code="c">2019</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Baden-Baden</subfield><subfield code="b">Nomos</subfield><subfield code="c">2019</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">München</subfield><subfield code="b">C.H.Beck</subfield><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xxi, 298 Seiten</subfield><subfield code="b">Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Civil justice systems</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Produzentenhaftung</subfield><subfield code="0">(DE-588)4047375-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelüberwachung</subfield><subfield code="0">(DE-588)4437717-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Internationales Wirtschaftsrecht</subfield><subfield code="0">(DE-588)4027461-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Medizinprodukt</subfield><subfield code="0">(DE-588)4024018-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">Großbritannien</subfield><subfield code="0">(DE-588)4022153-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Medizinprodukterecht</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Haftung</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Litigation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pharmaprodukte</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Produkthaftung</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medical device sector</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Internationales Wirtschaftsrecht</subfield><subfield code="0">(DE-588)4027461-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Medizinprodukt</subfield><subfield code="0">(DE-588)4024018-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Produzentenhaftung</subfield><subfield code="0">(DE-588)4047375-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Großbritannien</subfield><subfield code="0">(DE-588)4022153-2</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Arzneimittelüberwachung</subfield><subfield code="0">(DE-588)4437717-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="3"><subfield code="a">Produzentenhaftung</subfield><subfield code="0">(DE-588)4047375-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chakraborty, Sweta</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1189153246</subfield><subfield code="4">aut</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Nomos Verlagsgesellschaft</subfield><subfield code="0">(DE-588)117513-0</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Verlag C.H. Beck</subfield><subfield code="0">(DE-588)1023902869</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, PDF</subfield><subfield code="z">978-1-50991-672-6</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, PDF</subfield><subfield code="z">978-1-50991-673-3</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="q">text/html</subfield><subfield code="u">http://deposit.dnb.de/cgi-bin/dokserv?id=9d728e4b6ae64a19a144864a7e29a9f8&prov=M&dok_var=1&dok_ext=htm</subfield><subfield code="3">Inhaltstext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030666384&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030666384</subfield></datafield></record></collection>
geographic	USA (DE-588)4078704-7 gnd Großbritannien (DE-588)4022153-2 gnd
geographic_facet	USA Großbritannien
id	DE-604.BV045278756
illustrated	Not Illustrated
indexdate	2024-07-10T08:13:42Z
institution	BVB
institution_GND	(DE-588)117513-0 (DE-588)1023902869
isbn	9781509916696 9783848754632 9783406737145
language	English
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-030666384
open_access_boolean
owner	DE-M382
owner_facet	DE-M382
physical	xxi, 298 Seiten Diagramme
publishDate	2019
publishDateSearch	2019
publishDateSort	2019
publisher	Hart Publishing Nomos C.H.Beck
record_format	marc
series2	Civil justice systems
spelling	Macleod, Sonia Verfasser (DE-588)1178737772 aut Pharmaceutical and medical device safety a study in public and private regulation Sonia Macleod and Sweta Chakraborty First published 201903 Oxford Hart Publishing 2019 Baden-Baden Nomos 2019 München C.H.Beck 2019 xxi, 298 Seiten Diagramme txt rdacontent n rdamedia nc rdacarrier Civil justice systems Produzentenhaftung (DE-588)4047375-2 gnd rswk-swf Arzneimittelüberwachung (DE-588)4437717-4 gnd rswk-swf Internationales Wirtschaftsrecht (DE-588)4027461-5 gnd rswk-swf Medizinprodukt (DE-588)4024018-6 gnd rswk-swf USA (DE-588)4078704-7 gnd rswk-swf Großbritannien (DE-588)4022153-2 gnd rswk-swf Medizinprodukterecht Haftung Litigation Pharmaprodukte Produkthaftung medical device sector Internationales Wirtschaftsrecht (DE-588)4027461-5 s Medizinprodukt (DE-588)4024018-6 s Produzentenhaftung (DE-588)4047375-2 s DE-604 USA (DE-588)4078704-7 g Großbritannien (DE-588)4022153-2 g Arzneimittelüberwachung (DE-588)4437717-4 s Chakraborty, Sweta Verfasser (DE-588)1189153246 aut Nomos Verlagsgesellschaft (DE-588)117513-0 pbl Verlag C.H. Beck (DE-588)1023902869 pbl Erscheint auch als Online-Ausgabe, PDF 978-1-50991-672-6 Erscheint auch als Online-Ausgabe, PDF 978-1-50991-673-3 X:MVB text/html http://deposit.dnb.de/cgi-bin/dokserv?id=9d728e4b6ae64a19a144864a7e29a9f8&prov=M&dok_var=1&dok_ext=htm Inhaltstext DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030666384&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis
spellingShingle	Macleod, Sonia Chakraborty, Sweta Pharmaceutical and medical device safety a study in public and private regulation Produzentenhaftung (DE-588)4047375-2 gnd Arzneimittelüberwachung (DE-588)4437717-4 gnd Internationales Wirtschaftsrecht (DE-588)4027461-5 gnd Medizinprodukt (DE-588)4024018-6 gnd
subject_GND	(DE-588)4047375-2 (DE-588)4437717-4 (DE-588)4027461-5 (DE-588)4024018-6 (DE-588)4078704-7 (DE-588)4022153-2
title	Pharmaceutical and medical device safety a study in public and private regulation
title_auth	Pharmaceutical and medical device safety a study in public and private regulation
title_exact_search	Pharmaceutical and medical device safety a study in public and private regulation
title_full	Pharmaceutical and medical device safety a study in public and private regulation Sonia Macleod and Sweta Chakraborty
title_fullStr	Pharmaceutical and medical device safety a study in public and private regulation Sonia Macleod and Sweta Chakraborty
title_full_unstemmed	Pharmaceutical and medical device safety a study in public and private regulation Sonia Macleod and Sweta Chakraborty
title_short	Pharmaceutical and medical device safety
title_sort	pharmaceutical and medical device safety a study in public and private regulation
title_sub	a study in public and private regulation
topic	Produzentenhaftung (DE-588)4047375-2 gnd Arzneimittelüberwachung (DE-588)4437717-4 gnd Internationales Wirtschaftsrecht (DE-588)4027461-5 gnd Medizinprodukt (DE-588)4024018-6 gnd
topic_facet	Produzentenhaftung Arzneimittelüberwachung Internationales Wirtschaftsrecht Medizinprodukt USA Großbritannien
url	http://deposit.dnb.de/cgi-bin/dokserv?id=9d728e4b6ae64a19a144864a7e29a9f8&prov=M&dok_var=1&dok_ext=htm http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030666384&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
work_keys_str_mv	AT macleodsonia pharmaceuticalandmedicaldevicesafetyastudyinpublicandprivateregulation AT chakrabortysweta pharmaceuticalandmedicaldevicesafetyastudyinpublicandprivateregulation AT nomosverlagsgesellschaft pharmaceuticalandmedicaldevicesafetyastudyinpublicandprivateregulation AT verlagchbeck pharmaceuticalandmedicaldevicesafetyastudyinpublicandprivateregulation

Verfügbarkeit

Es ist kein Print-Exemplar vorhanden.

Fernleihe Bestellen Achtung: Nicht im THWS-Bestand! Beschreibung

MARC

Datensatz im Suchindex

Es ist kein Print-Exemplar vorhanden.

Ähnliche Einträge